Association between a low baseline level of gene expression of energy metabolism in the blood and the development of clinical remission in response to tofacitinib therapy in patients with rheumatoid arthritis
Open Access
- 24 June 2021
- journal article
- research article
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (3) , 20-26
Abstract
Background. Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology, characterized by erosive arthritis (synovitis) and systemic inflammation. Janus kinase (JAK) inhibitors (JAKi) are small molecules that block major signal pathways of many cytokines a growth factors, associated with RA. Identification of patients sensitive to JAKi before treatment could significantly improve therapy outcomes. Currently it is not possible to predict JAKi efficacy in every patient, while some patients are non-responsive to the drug, other develop adverse effects. JAKi effect in RA patients has been recently associated with alterations in mitochondrial function and ATP production. Therefore, we hypothesized that baseline metabolic status of RA patients prior to drug administration can predict the therapeutic outcome.Objective: to investigate the predictive value of baseline expression of genes involved in energy generation in the blood of RA patients, for treatment response to JAKi.Patients and methods. We examined peripheral blood of 28 RA patients aged 52.2±15.6 years, average disease duration 3.5 years (range 0.6–19), treated with Tofacitinib (TOFA, 5–10 mg twice a day) during three months and 26 healthy age-matched control subjects. Clinical response was assessed by disease activity score (DAS28-ESR), immunological status by measurements of serum levels of anti-citrullinated protein antibodies (ACPA), rheumatoid factor (RF), and C-reactive protein (CRP). Gene expression was assessed in peripheral blood cells by realtime reverse-transcription polymerase chain reaction (RT-PCR). At baseline all patients had Steinbrocker radiographic stage II–III. Most patients (85.7%) were ACPA and RF positive. Thirteen patients had medium, others – high RA activity.Results and discussion. JAKi treatment significantly decreased the inflammatory disease activity according to DAS28. At the end of the study 17 patients demonstrated moderate disease activity (3.2Conclusion. Clinical remission in RA patients treated with JAKi is associated with significantly lower baseline expression of genes associated with energy generation pathways (PKM2 and SDHB) compared to other examined subjects.Keywords
This publication has 21 references indexed in Scilit:
- The Jak/STAT pathway: A focus on pain in rheumatoid arthritisSeminars in Arthritis and Rheumatism, 2021
- Why remission is not enough: underlying disease mechanisms in RA that prevent cureNature Reviews Rheumatology, 2020
- Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic ApproachDrugs, 2020
- JAK/STAT Blockade Alters Synovial Bioenergetics, Mitochondrial Function, and Proinflammatory Mediators in Rheumatoid ArthritisArthritis & Rheumatology, 2018
- Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators?Pharmacological Research, 2018
- Pathogenetic insights from the treatment of rheumatoid arthritisThe Lancet, 2017
- Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled TrialArthritis Care & Research, 2017
- The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery diseaseJournal of Experimental Medicine, 2016
- Rheumatoid arthritis: What is refractory disease and how to manage it?Autoimmunity Reviews, 2011
- Rheumatoid ArthritisNew England Journal of Medicine, 1990